Skip to main content

Table 4 Incidence of major complications in different models of anticoagulant therapy in real world in patients with recurrent venous thromboembolism (VTE)

From: Patient self-management of oral anticoagulation with vitamin K antagonists in everyday practice: clinical outcomes in a single centre cohort after long-term follow-up

 

Incidence of major complications (% pt-yr)

Author

Year

Drug

N

Mean age (years)

Total follow-up

(pt-ys)

Mean follow-up

(years)

Haemorrhagic

Thrombotic

Totalb

Mortality

PSM of VKA

 Nagler [8]b

2014

VKA

451

48.5

1939a

4.3a

0.9

0.5

1.4a

1.1

 Larsen [10]

2016

VKA

444

46.6

1953

6.9

0.4

1.3

1.7a

0.5

Our study

2018

VKA

213

47.5

1288

6.0

0.2

0.6

0.9

0.4

Conventional management of VKA in highly specialized centres

 Wieloch [23]

2011

VKA

1146

66

802

0.7a

2.6

1.8

4.4a

NR

 Sjöegren [24]

2015

VKA

17,219

65.3

48213a

2.8a

2.0

1.1

3.1a

NR

 Larsen [10]

2016

VKA

2220

46.8

9569

6.7

0.4

2.2

2.6a

1.1

Conventional management of VKA

 Ageno [44]

2016

VKA

2149

66.0

1719a

0.8a

2.3

2.6

4.9a

4.1

 Sindet-Pedersen [45]

2017

VKA

6907

66

3453a

0.5

2.1

3.1

5.2a

NR

 Coleman [46]

2017

VKA

32,244

43% > 60

16122a

0.5

1.0

3.5

4.5a

NR

 Weycker [47]

2018

VKA

17,878

60

7437a

0.4

5.5

7.0

12.5a

NR

DOACs

 Ageno [44]

2016

Rivaroxaban

2619

59.0

1833a

0.7a

0.7

1.4

2.1a

0.5

 Sindet-Pedersen [45]

2017

Rivaroxaban

5411

66

2705a

0.5

2.3

3.0

5.3a

NR

 Coleman [46]

2017

Rivaroxaban

13,609

42% > 60

6804a

0.5

0.8

2.8

3.6a

NR

 Berger [48]

2018

Rivaroxaban

3763

57.2

1656a

0.44

1.1

1.4

2.5a

NR

 Weycker [47]

2018

Apixaban

17,878

60

7008a

0.4

4.2

5.8

10.0a

NR

  1. The incidences in Ageno et al [44] and Sindet-Pedersen et al [45] were in % patients, not in % pt-ys
  2. a Approximated value; NR not reported
  3. b Total major complications were approximated as the sum of haemorrhagic plus thromboembolic, if not explicitly given in the publication